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Abstract
Purpose The objectives of this study were to examine the
differences in health status (HS) of women with breast
cancer (BC) at different moments in time, and between
women scoring high and not high on trait anxiety, and to
identify possible predictors of HS 6 and 12 months after
surgery.
Methods Patients (N = 223) completed a trait anxiety
questionnaire before diagnosis. Women who received a
diagnosis of BC completed a BC-specific HS questionnaire
1, 3, 6 and 12 months after surgery. ANCOVA for repeated
measures and multiple regression analysis were used in the
analyses.
Results Women scoring high on trait anxiety had signif-
icant (P \ .005) lower Body image, worse Future per-
spective and Sexual functioning, and more Side-effects
than women who did not score high on trait anxiety. At 6
and 12 months after surgery, the same aspects of HS were
predicted by higher trait anxiety scores.
Conclusions Higher scores on trait anxiety resulted in
worse scores on four HS domains, indicating that there
should be more attention for this group of patients, even
before treatment starts.
Keywords Oncology  Breast cancer  Health status 
Trait anxiety  Treatment
Introduction
Breast cancer is the most widespread form of cancer in
Europe [1]. Since incidence rates are still increasing but
mortality is decreasing [1, 2], more and more women are
survivors of breast cancer. For these women, health status
(HS), defined as ‘‘well-being in terms of physical, mental,
and social condition’’ [3], is an important outcome, next to
their medical condition. HS has been examined in different
studies with various measures, for instance among long-
term survivors ([5 years) of breast cancer [4]. In these
women, overall HS was fairly good. The most frequently
reported complaints were sexual problems and arm prob-
lems [4]. When HS was measured within 2 years after
diagnosis, DiSipio et al. [5] found that younger breast
cancer survivors (\50 years) 1 year after diagnosis had a
HS comparable with the normal population. Women of
50 years and older already had a HS comparable with the
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normal population 6 months after diagnosis. Inconsistent
with these results, other studies noted that 1 year after
surgery, cognitive and social functioning in breast cancer
survivors were impaired compared with the normal popu-
lation [6], and the HS of younger women was more
impaired than that of older women [7, 8]. There are recent
studies that indicate that HS is also affected by socio-
economic status and comorbidity [9, 10].
A factor that is associated with the level of HS in breast
cancer patients, although not studied frequently, is trait
anxiety, i.e. the disposition to experience anxiety in
threatening situations. Schreier et al. [11] for example,
found that trait anxiety correlates negatively with HS
scores in breast cancer patients. Trait anxiety also predicted
higher levels of distress in breast cancer patients [12], with
higher levels of distress being directly related to a decrease
in HS [13]. A recent study in patients with rectal cancer
showed that higher trait anxiety levels predicted worse HS
[14].
In this longitudinal, prospective study, trait anxiety was
measured in patients before they received a diagnosis.
Subsequently, HS was measured at different moments in
time after diagnosis and treatment. This makes it possible
to look at the relation between trait anxiety and the dif-
ferent aspects of HS, as well as looking at the course of HS
in time.
The goals of this study were to examine (1) whether
women who score high on trait anxiety have a different HS
across time compared with women who do not score high
on trait anxiety, and (2) which factors predict HS 6 months
and 1 year after surgery. The expectation was that women
who scored high on trait anxiety had a worse HS than
women who did not score high on trait anxiety. Further-
more, trait anxiety was expected to predict HS at 6 and
12 months after surgery.
Methods and patients
Patients
This study was part of a larger study, concerning the
relationship between personality, surgical treatment and
quality of life in women with early-stage breast cancer. In
this larger study, all women visiting the outpatient clinic of
the St Elisabeth Hospital in Tilburg (from January 2002
until June 2007), the Maasland Hospital in Sittard (from
June 2004 until March 2006), and the Jeroen Bosch Hos-
pital in Den Bosch (from January 2006 until June 2007),
The Netherlands, were asked to participate. They were
referred by their general practitioner with either a palpable
lump in the breast or an abnormality on the screening
mammography and a negative medical history for breast
disease. At their first appointment with a specialized
mamma-care nurse (a nurse who is specialized in the care
for breast cancer patients), they were informed about the
study and when women agreed to participate, they com-
pleted an informed consent and a set of questionnaires
(Time 1). This was before they knew the diagnosis of the
breast problem they visited the outpatient clinic for. Of the
799 women who visited one of the outpatient clinics with a
problem of the breast, 286 (35.8%) were diagnosed with
early-stage breast cancer. The other 513 (64.2%) patients
appeared to have a benign breast problem. Of the 286
women with breast cancer, 223 (78%) completed the first
set of questionnaires, including a questionnaire about trait
anxiety. Patients with breast cancer included in this study
were in the situation that they had a choice in their surgical
treatment: they could choose either for breast conserving
therapy (BCT) or for mastectomy (MTC). The breast
cancer patients received additional questionnaires at 1
(Time 2), 3 (Time 3), 6 (Time 4) and 12 months (Time 5)
after surgical treatment (see Fig. 1). Exclusion criteria for
the current study were not being able to speak and/or read
Dutch, having cognitive problems, a medical history with
breast disease, advanced-stage breast cancer or a benign
breast problem. This study was approved by the Medical
Ethical Committee (ccMo NL15659.008.06).
Questionnaires
HS was measured at Time 2, Time 3, Time 4, and Time 5
using the validated disease-specific European Organisation
for Research and Treatment of Cancer Quality of Life
Questionnaire Breast Cancer module (EORTC QLQ-
BR23) [15, 16]. This 23-item questionnaire is developed
for breast cancer patients at different stages of their disease
and with varying treatment modalities. The EORTC QLQ-
BR23 measures the functional scales Body image (4 items),
Sexual functioning (2 items), Sexual enjoyment (1 item;
179 participants 1month after surgery
165 participants 12 months after surgery
168 participants 6 months after surgery
172 participants 3 months aftersur gery
Drop-out 3 
Drop-out 4 
Drop-out 7 
Total drop-out 
58 (26%)
223 participants before surgery
Drop-out 44 
Fig. 1 Flowchart of the study
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only to be completed when patient is sexually active), and
Future perspective (1 item; ‘‘Were you worried about your
health in the future?’’) and the disease symptom scales
Systemic therapy side-effects (7 items), Breast symptoms
(4 items), Arm symptoms (3 items), and Upset by hair loss
(1 item; only to be completed if patient had hair loss).
Answers vary from 1 (not at all) to 4 (very much). Higher
scores on the functional scales represent a higher level of
functioning, while higher scores on the symptom scales
represent more symptomatology.
Trait anxiety was measured at Time 1 with the trait
anxiety subscale of the State-Trait Anxiety Inventory
(STAI) at Time 1 [17, 18]. The STAI measures trait anxiety
with 20 items. Answers range from 1 (almost never) to 4
(almost always). It is a frequently used questionnaire with
good psychometric properties [18]. For some analyses, the
scores on trait anxiety were dichotomized in high or not
high. A cut-off score of 44 or higher was used to determine
high trait anxiety [18]. The definition of this cut-off score
was based on normative data for women between 40 and
59 years [19] and was construed using the mean score
(34.2) plus 1 SD (9.87).
Demographic variables included in the study were age and
marital status. Level of education and work status were
assessed to use as an approximation of socio-economic status.
Medical records
The following information was retrieved from patients’
medical files: the disease stage at diagnosis [20], type of
operation, and adjuvant treatment (chemotherapy, radio-
therapy, hormone treatment).
Statistical procedure
For baseline measures, Chi-square (discrete variables) and
independent samples T tests (continuous variables) were
used to compare participants and non-participants, and the
trait anxiety groups (dichotomized in high or not high) with
regard to age, partner, children, education, work, disease
stage at diagnosis, level of trait anxiety, surgical treatment,
and adjuvant treatment. ANCOVA for repeated measures
was used to examine differences in HS scores between
measurements in time and between patients with different
trait anxiety scores (dichotomized in high or not high).
Additionally, univariate regression analysis was used to
select factors for the multivariate linear regression analyses
(MRA). The dependent variables in the univariate regres-
sion were Body image, Sexual functioning, Future per-
spective, Systemic therapy side-effects, Breast symptoms
and Arm symptoms at T4 and T5. Independent variables
were age, partner yes/no, children yes/no, education, work
yes/no, level of trait anxiety (continuous total score),
screening referral yes/no, disease stage at diagnosis, sur-
gical treatment, adjuvant therapy yes/no, chemotherapy
yes/no, radiotherapy yes/no, and hormone therapy yes/no.
The significant independent variables of the univariate
regression analysis were imported in the backward MRA
that was performed to identify those factors that best pre-
dicted patients’ scores on the EORTC QLQ-BR23 at Time
4 and Time 5. All analyses were performed with the Sta-
tistical Package for Social Sciences (SPSS) version 14.0.
Results
Of 286 eligible women with breast cancer, 223 (78%)
participated in the study. There were no differences in age,
disease stage, type of operation, and receiving adjuvant
therapy between participants and non-participants. Demo-
graphic and medical information of participants is sum-
marized in Table 1.
About 40% was diagnosed with disease stage I. Regarding
surgical treatment, 107 women had BCT and 114 women
received MTC. Women with BCT and MTC significantly
differed on receiving adjuvant therapy and disease stage; i.e.
BCT patients more often had adjuvant therapy (P \ .001)
and were in a lower disease stage at diagnosis (P = .002).
Women scoring high on trait anxiety (37%) had a lower
education level (P = .005) and were older (P = .041) than
women not scoring high on trait anxiety. There were no
differences concerning other demographic and medical
factors. Disease stage, receiving adjuvant therapy, type of
surgery, educational level, and age were included as covar-
iates in the subsequent analyses. During the study, 58 women
(26%) dropped out within 12 months after surgery. Reasons
for drop-out were ‘not interested’, ‘do not want to be con-
fronted with the past,’ or ‘too much work’ (Fig. 1). Partici-
pants and drop-outs only differed on age (P = .008), with
drop-outs being older than participants.
In the MRA, the total score on trait anxiety was included
following the goal of the study. Age, disease stage, receiving
adjuvant therapy, type of surgery, and educational level
were included because these factors differed between
groups. In addition, significant factors of the univariate
analyses were included, namely chemotherapy and screen-
ing referral for Body image, marital status for Sexual
functioning, chemotherapy and hormone therapy for Sys-
temic therapy side-effects, and children, radiotherapy, and
screening referral for Breast symptoms (see Table 2).
Functional scales
The high trait anxiety group had a lower Body image than
the no-high group (P = .003). The covariate type of sur-
gery was also significant. The BCT group had a higher
Qual Life Res (2011) 20:865–873 867
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Body image than the MTC group at all measurements
(P = .006). More positive Body image scores at Time 4
and Time 5 was predicted by lower scores on trait anxiety,
BCT, and older age. Receiving chemotherapy predicted a
more negative Body image, but only at Time 4 (Table 3).
Women who did not score high on trait anxiety had a
more positive Future perspective than women who did
score high on trait anxiety (P \ .001) (see Fig. 2). The
latter group had a more unusual course of Future per-
spective. Between Time 3 and Time 4 their Future per-
spective dropped seriously (P \ .001). At Time 5, their
Future perspective had increased to approximately their
Time 2 level. This pattern is reflected in the interaction
effect of time and trait anxiety (P \ .001).
More positive Future perspective at Time 4 was pre-
dicted by lower scores on trait anxiety and older age. Trait
Table 2 Outcomes of the univariate regression analyses of demographic and medical factors on the EORTC QLQ-BR23 domains: P values
BI T4 FP T4 SF T4 SE T4 BS T4 AS T4 BI T5 FP T5 SF T5 SE T5 BS T5 AS T5
Age .002 .025 .001
Screening referral .014 .042
STAI total score .006 \.001 \.001 .004 .034 .020 \.001 .011 .008 .022
Adjuvant treatment .016
Chemotherapy .001 \.001 .038
Radiotherapy .003 \.001
Hormonal treatment .029
Type of surgery .001 .007 .005 \.001
Disease stage .045 .003
Educational level .017 .018 .012
Children .017
Work
Partner .007 \.001
BI Body image, FP future perspective, SF sexual functioning, SE systemic therapy side-effects, BS breast symptoms, AS arm symptoms, T4
measurement 6 months after surgical treatment, T5 measurement 12 months after surgical treatment
Note: Only significant results are shown
Table 1 Demographic and
medical information of the
breast cancer patients
(N = 223)
* Screening referral Women
referred by the national breast
cancer screening program
Demographic information Medical information
Age Screening referral*
Mean ± SD 58.7 ± 9.4 Yes 151 (67.7%)
Partner No 72 (32.3%)
Yes 179 (80.2%) Disease stage
No 37 (16.6%) Stage 0 24 (10.8%)
Missing 7 (3.1%) Stage I 93 (41.7%)
Children Stage IIa 70 (31.4%)
Yes 191 (85.7%) Stage IIb 35 (15.7%)
No 29 (13.0%) Indefinable 1 (0.4%)
Missing 3 (1.3%) Type of operation
Educational level Breast conserving therapy 107 (48.0%)
Low 85 (38.1%) Mastectomy 114 (51.1%)
Middle 95 (42.6%) No operation 2 (0.9%)
High 37 (16.6%) Adjuvant therapy
Missing 6 (2.7%) Received chemotherapy 60 (26.9%)
Work status Received radiotherapy 117 (52.2%)
Employed 85 (38.1%) Received hormone treatment 87 (39.0%)
Unemployed 135 (60.5%)
Missing 3 (1.3%)
868 Qual Life Res (2011) 20:865–873
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anxiety was the only predictor of more positive Future
perspective at Time 5 (Table 3), i.e., lower scores on trait
anxiety predicted higher Future perspective.
The women with a high score on trait anxiety reported
lower Sexual functioning than the other women (P =
.002). There was an interaction effect between time and
chemotherapy, showing that the course of Sexual func-
tioning for women with or without chemotherapy differed
across time (P = .045). Two different factors predicted
better Sexual functioning at Time 4 and Time 5, namely
lower scores on trait anxiety and having a partner. Younger
age was a predictor of a higher level of Sexual functioning
at Time 5 (Table 3).
Symptom scales
Women high on trait anxiety reported more Side-effects
than the other women (P = .001) (Fig. 3). There was
an interaction effect between time and chemotherapy
(P = .012) reflecting that women without chemotherapy
have a constant level of Side-effects across time and
women with chemotherapy experienced a major increase in
Side-effects 3 months after surgery. Side-effects decreased
toward 12 months after surgery, but the level stayed above
that of women without chemotherapy. Receiving chemo-
therapy and having a higher score on trait anxiety were
significant predictors of more Side-effects at Time 4. At
Table 3 Predictors of the
functional scales at 6 and
12 months after surgery
6 months after surgery 12 months after surgery
b P Tot. adj. R2 b P Tot. adj. R2
Body image
Trait anxiety -.311 \.001 -.257 .002
Type of surgery -.239 .002 -.266 .001
Age .259 .001 .256 .002
Chemotherapy -.173 .031 23.5% 15.7%
Future perspective
Trait anxiety -.497 \.001 -.335 \.001
Age .166 .025 25.0% 10.5%
Sexual functioning
Trait anxiety -.330 \.001 -.232 .007
Partner .192 .023 .277 .002
Age 13.2% -.212 .015 17.5%
12 months after 
surgery
6 months after 
surgery
 3 months after 
surgery
1 month after 
surgery
75,00
70,00
65,00
60,00
55,00
50,00
45,00
40,00
Sc
or
es
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n 
Fu
tu
re
 P
er
sp
ec
tiv
e 
Sc
al
e
Future Perspective
high
not high
trait anxiety
Fig. 2 Scores on the Future Perspective scale of the EORTC QLQ-
BR23 for women scoring high and not high on trait anxiety
Fig. 3 Scores on the Systemic Therapy Side-effects scale of the
EORTC QLQ-BR23 for women scoring high and not high on trait
anxiety
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Time 5, only higher scores on trait anxiety significantly
predicted more Side-effects (see Table 4).
Trait anxiety did not interfere with Breast symptoms,
but type of surgery did. BCT resulted in significantly
(P = .007) more Breast symptoms than MTC. More Breast
symptoms at Time 4 were predicted by receiving radio-
therapy, a lower educational level and not having children.
Educational level remained a predictor at Time 5, and
receiving BCT predicted more Breast symptoms (Table 4).
Arm symptoms differed between women in different
disease stages (P = .015). A higher disease stage resulted
in more Arm symptoms. Worse scores on Arm symptoms
at Time 4 and Time 5 were predicted by lower educational
level (see Table 4).
Discussion
In this study, we examined the relationship between trait
anxiety and HS, taking into account multiple demographic,
personality, and medical factors. HS contains six domains
in this study, and four of those domains, namely Body
image, Future perspective, Sexual functioning, and Side-
effects were negatively affected by trait anxiety.
Trait anxiety
One of the goals of this study was to examine whether there
were differences in HS between women who scored high
on trait anxiety and women who did not score high on trait
anxiety. Based on earlier studies [11, 12, 21], we expected
that women with a high score on trait anxiety would have
lower scores on HS. Indeed trait anxiety seemed to play an
important role in the HS of women with breast cancer,
especially with regard to Body image, Future perspective,
Sexual functioning, and Side-effects. On these scales of the
EORTC QLQ-BR23, women who scored high on trait
anxiety had significant worse outcome than women who
did not score high on trait anxiety, even 12 months after
surgical treatment. A remarkable result was, for example,
the course of Future perspective of women with high scores
on trait anxiety (see Fig. 2). There is a significant decrease
in their Future perspective 6 months after surgery took
place. An explanation could be that when treatment has
ended, patients are uncertain about how to pick up their
lives.
Furthermore, trait anxiety was the only factor that sig-
nificantly and negatively predicted Body image, Future
perspective and Sexual functioning at 6 and 12 months
after surgery, implying that other factors such as disease
stage and treatment have less impact on HS than this per-
sonality trait. Comparable results were found in three other
studies, even though in these studies (HR) QoL [11, 21]
and psychological stress [12] were used as outcome
measures.
Moreover, higher trait anxiety predicted more Systemic
therapy side-effects at 6 and 12 months after surgery (see
Fig. 3). This could be due to the fact that patients scoring
high on trait anxiety believe that they will experience more
side-effects of their systemic therapy, as mentioned in the
study of Cameron and colleagues [22]. There was no rela-
tion between trait anxiety and Arm and Breast symptoms.
Demographic factors
Another factor besides trait anxiety that predicted more
than one domain of HS was age. Older age predicts a better
Body image at 6 and 12 months after surgery and a more
positive perspective on the future at 6 months after surgery.
Multiple explanations could be considered here. One pos-
sibility is that younger women more often have an
advanced stage of breast cancer, or a more aggressive
tumor. In these cases, treatment can be more invasive and
mutilating and more often includes chemotherapy, which is
Table 4 Predictors of the
symptoms scales at 6 and
12 months after surgery
6 months after surgery 12 months after surgery
b P Tot. adj. R2 b P Tot. adj. R2
Side-effects
Chemotherapy .340 \.001
Trait anxiety .299 \.001 16.9% .249 .005 5.3%
Breast symptoms
Radiotherapy .251 .002
Children -.233 .004
Educational level -.223 .006 -.224 .008
Type of surgery 14.3% -.378 \.001 17.3%
Arm symptoms
Educational level -.204 .016 3.5% -.177 .048 2.3%
870 Qual Life Res (2011) 20:865–873
123
also a predictor for worse HS [5, 7]. Another explanation
could be that a diagnosis of BC and the subsequent treat-
ment possibly disrupts the course of life more in younger
women than in older women [23, 24].
Contrary to the previous result where older age was
related to more positive outcomes, better Sexual func-
tioning at 12 months after surgery was predicted by
younger age. Presumably, this has a relation with meno-
pause and menopausal symptoms. Most of the older
women have past their menopause, but in younger women,
only those who had systemic therapy might have meno-
pausal symptoms which can lead to decreased sexual
enjoyment [7]. This relation between age and Sexual
functioning was also found in other studies that used the
EORTC QLQ-BR23 [25, 26].
Other demographic factors with an influence on HS
were educational level, having children, and having a
partner. A higher educational level predicted less Breast
and Arm symptoms at 6 months after surgery, and less
Breast symptoms at 12 months after surgery. Earlier
research revealed the same relation between education and
Breast and Arm symptoms [27]. A possible reason for this
could be that higher educated women are more likely to
learn about how to take care of their wounds and how to
exercise and use their arm. Having children predicted less
Breast symptoms at 6 months after surgery, and having a
partner predicted better Sexual functioning at 6 and
12 months after surgery.
Disease-specific factors: treatment
Type of surgery had a significant relation with Body image:
women that had BCT had a better Body image than women
that had MTC, during the 12 months after surgery. This
outcome is also supported by multiple studies [28–30]. A
more unexpected result was that women with BCT reported
much more Breast symptoms than women that had MTC.
BCT also significantly predicted more Breast symptoms at
Time 5. Since MTC is medically more invasive than BCT,
it would be obvious to expect that MTC causes more Breast
symptoms. The current outcome could possibly be attrib-
uted to treatment features: in BCT radiotherapy is part of
regular treatment, while women that have MTC almost
never receive radiotherapy. Radiotherapy can therefore not
be seen apart from type of surgical treatment. From the
regression analysis, we also learned that not receiving
radiotherapy was a predictor for less Breast symptoms.
These facts together can obviously explain why women
with BCT have more Breast symptoms: radiotherapy can
cause irritation of the skin and wounds heal slower [31].
Another possible explanation is a linguistic one: in the
questionnaire, women are asked about complaints in the
area of their affected breast. Perhaps, women that had an
MTC reason that they do not have a breast anymore (for
MTC removes the breast in total), and they do not report
possible complaints as complaints of their breast. In the
study of King et al. [27], there was no significant difference
reported in Breast symptoms between BCT and MTC, and
apart from that study there is no specific literature about
this topic, so more research is needed to clarify this result.
Besides type of surgery, there were other treatment
factors that predicted HS. Receiving chemotherapy pre-
dicted more Side-effects and worse Body image at Time 4.
Radiotherapy predicted worse Future perspective and more
Breast symptoms at Time 4. These results are in line with a
recent study on adjuvant therapy and HR-QoL [32]. In
contrast to what Buijs et al. [33] found, there was a relation
between hormone therapy and Arm symptoms: receiving
hormone therapy predicted less Arm symptoms at Time 5.
This could have a relation with other factors, like radio-
therapy, but more research needs to be done about this
topic.
Limitations of this study
In this study, only women with early-stage breast cancer
were included (see Table 1). An advantage is the homoge-
neity of the data, but the disadvantage is that it is not pos-
sible to generalize the conclusions to other patient groups,
such as late-stage or recurrent breast cancer patients. Fur-
thermore, there was a selection effect on two items of the
EORTC QLQ-BR23: the items about ‘Upset by hair loss’
and ‘Sexual enjoyment’ only had to be answered if women
actually did have hair loss or were sexually active, respec-
tively. Due to these criteria, not enough patients answered
the questions to evaluate them in this study. To counter this
problem and other potential power problems, more women
need to be included in future research.
In this study, radiotherapy was introduced as an inde-
pendent variable. We realize that there is an overlap
between radiotherapy and type of surgery, i.e. usually
women who receive BCT also get radiotherapy. Likewise,
radiotherapy is usually not a part of MTC treatment.
However, because in this study there were 10 women
(9.3% of BCT) who received BCT but not radiotherapy,
and 20 women (17.5% of MTC) who received MTC and
radiotherapy, we decided to maintain radiotherapy as an
independent variable.
In conclusion, trait anxiety is strongly associated with
the HS of breast cancer patients in the first year after sur-
gery. This insight into the personality of patients could be a
first indication of better monitoring patients that have a
higher risk of having a worse HS after diagnosis and
treatment of their disease. Since HS is an important end-
point of treatment in breast cancer patients nowadays,
psychosocial support should be deployed to guide these
Qual Life Res (2011) 20:865–873 871
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high-risk patients through the process of their disease and
possibly thereafter.
Furthermore, it should not be accepted unquestioningly
that women who had BCT do better than women with
MTC. The results from this study pointed out that even
though BCT is, medically spoken, a less invasive treatment
than MTC, BCT patients can have serious Breast symp-
toms. There should therefore be close attention for medical
and psychosocial symptoms in women with MTC and
BCT.
The results of this study also have clinical implications.
Based on the present results, women scoring high on
anxiety are prone to experiencing more side-effects. Psy-
chological counseling aimed at these women could prob-
ably reduce side-effects. However, in order to provide this
treatment, high anxious women should be identified using
short, validated easy-to-administer trait anxiety question-
naires, such as the STAI [17, 18].
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